Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.606 USD | +0.48% | +1.56% | -65.43% |
22/04 | North American Morning Briefing : Stock Futures -2- | DJ |
19/04 | Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63 | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-65.43% | 20.88M | C | ||
+1.49% | 12.8B | B+ | ||
-10.29% | 7.61B | B- | ||
+2.75% | 5.41B | B | ||
-1.16% | 4.51B | C | ||
+8.05% | 4.49B | C | ||
+12.21% | 2.73B | - | - | |
-13.71% | 2.02B | B- | ||
-11.50% | 1.73B | D+ | ||
-0.05% | 1.64B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DMTK Stock
- Ratings DermTech, Inc.